Overview
Alecensa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an…

Overview
Alimta is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of non-squamous non-small cell lung cancer (NSCLC). Alimta can be used in different ways depending on the stage and type of…

Overview
Alunbrig is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with ALK-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alunbrig is…

Overview
Augtyro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Augtyro is also referred to by…

Overview
Avastin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic, non-squamous, non-small cell lung cancer, as well as other types of cancer. Avastin is usually…

Overview
Bizengri is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval for the treatment of adults with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a…

Overview
Braftovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in…

Overview
Cyramza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC). Cyramza is often prescribed with erlotinib or docetaxel, two…

Overview
Datroway is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has an epidermal growth factor receptor…

Overview
Emrelis is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that shows high c-Met protein…

Overview
Enhertu is approved by the U.S. Food and Drug Administration (FDA) for treating adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and…

Overview
Ensacove is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who…

Overview
Gavreto is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer as…

Overview
Gemzar is approved by the U.S. Food and Drug Administration (FDA) for use in combination with the chemotherapy drug cisplatin for the treatment of non-small cell lung cancer (NSCLC). Gemzar is also known by its…

Overview
Gilotrif is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC) with nonresistant epidermal growth factor receptor mutations as…

Overview
Hernexeos is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable (cannot be removed by surgery) or metastatic (spread to other parts of the body) non-squamous…

Overview
Ibtrozi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that tests positive for ROS1 gene…

Overview
Imdelltra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive stage small cell lung cancer (SCLC) — cancer that has spread — whose disease has progressed…

Overview
Imfinzi is approved by the U.S. Food and Drug Administration (FDA) to treat certain types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It may be used as a single…

Overview
Imjudo is approved by the U.S. Food and Drug Administration (FDA) in combination with durvalumab and platinum-based chemotherapy for the treatment of adults with metastatic non-small cell lung cancer (NSCLC)…

verview

Iressa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic, non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or…

Overview
Keytruda is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic small cell lung cancer and various non-small cell lung cancers. Keytruda is also referred to by its…

Overview
Keytruda Qlex is approved by the U.S. Food and Drug Administration (FDA) for several types of non-small cell lung cancer (NSCLC). It is approved in combination with pemetrexed and a platinum-based chemotherapy…

Overview
Krazati is a brand name for the drug Adagrasib, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in adults. Specifically, it is used as a…

Overview
Lazcluze is approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that carries specific epidermal…

Overview
Libtayo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in adults. A person must have no EGFR, ALK, or ROS1 genetic mutations, and their cancer…

Overview
Lorbrena is approved by the U.S. Food and Drug Administration (FDA) for treating adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. The FDA requires an approved test to…

Overview
Lumakras is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least…

Overview
Mekinist is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with a mutation of the BRAF V600E gene as detected by an FDA-approved test…

Overview
Mektovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in…

Overview
Opdivo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer. Opdivo is often prescribed with ipilimumab (Yervoy). Opdivo is also known by…

Overview
Opdivo Qvantig is approved by the U.S. Food and Drug Administration (FDA) as part of a treatment regimen for non-small cell lung cancer (NSCLC) in certain scenarios. These include use in combination with…

Overview
Portrazza is approved by the U.S. Food and Drug Administration (FDA) for use in combination with the chemotherapy drugs gemcitabine and cisplatin for the first-line treatment of metastatic squamous non-small cell…

Overview
Retevmo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer. Retevmo…

Overview
Rozlytrek is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an…

Overview
Rybrevant is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer. It is specifically indicated for adults with locally advanced or metastatic non-small cell lung cancer…

Overview
Rybrevant Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that has specific…

Overview
Tabrecta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, non-small cell lung cancer whose tumors have a mutation known as mesenchymal-epithelial…

Overview
Tafinlar is a brand name for the drug Dabrafenib, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of individuals with metastatic non-small cell lung cancer (NSCLC) with the BRAF…

Overview
Tagrisso is approved by the U.S. Food and Drug Administration (FDA) for several indications related to non-small cell lung cancer (NSCLC). It is used as an adjuvant therapy (additional treatment following…

Overview
Taxotere is approved by the U.S. Food and Drug Administration (FDA) for use as a treatment for non-small cell lung cancer (NSCLC), along with other types of cancer. Taxotere is typically prescribed when prior…

Overview
Tecentriq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with small cell or non-small cell lung cancer by itself or as an adjuvant therapy (in combination with…

Overview
Tecentriq Hybreza, a combination of atezolizumab and hyaluronidase, is approved by the U.S. Food and Drug Administration (FDA) for treating various forms of lung cancer, including non-small cell lung cancer…

Overview
Tepmetko is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) who have MET exon 14 skipping alterations, as confirmed by a…

Overview

Vinorelbine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC). It may be prescribed either in combination with cisplatin for patients with locally…

Overview
Vitrakvi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance…

Overview
Vizimpro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21…

Overview
Xalkori is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC) with tumors that are positive for anaplastic lymphoma kinase (ALK) as…

Overview
Yervoy is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with tumors that express the protein PD-L1. Yervoy is prescribed in…

Overview
Zegfrovy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific mutations (changes) in the…

Overview
Zepzelca is approved by the U.S. Food and Drug Administration (FDA) for treating adults with metastatic (advanced) small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based…

Overview
Zykadia is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for anaplastic lymphoma kinase…